Features and clinical significance of inflammatory markers in patients with metabolic syndrome with and without coronary heart disease
Abstract
Aim. To study endothelial function in patients with metabolic syndrome in thepresence or absence of coronary artery disease.
Material and methods. Research included 82 male patients with existence of a metabolic syndrome aged from 39 to 72 years. Patients were divided into 2 groups after verification of the diagnosis. Group 1 (n = 40) patients without symptoms of coronary atherosclerosis made, group 2 (n = 42) – patients with existence of a coronary atherosclerosis.
Results. At patients with a metabolic syndrome and existence of an ischemic heart disease it is reliable above such markers of an inflammation bsCRP, IL-6, TFN-α, selectin and reliable there is lower than a level of cardioprotective protein of an apelin.
Conclusion. Definition of early predictors of coronary heart disease can significantly influence the individual program of treatment of the patient further.
About the Authors
A. A. Efremushkina
Altai State Medical University
Russian Federation
Russian Federation
656049
Lenin av., 40
Barnaul
D. M. Rudakova
KGBUZ Altai Regional Clinical Hospital
Russian Federation
Russian Federation
656024
Lyapidevskiy str., 1
Barnaul
E. N. Vorobyova
Altai State Medical University
Russian Federation
Russian Federation
656049
Lenin av., 40
Barnaul
References
1. Van Gaal L. F., Mertens I. L., De Blok C. E. Mechanisms linking obesity with cardiovascular disease // Nature. 2006. Vol. 444. P. 75–80.
2. Орлова Г. М. Метаболический синдром в Прибайкалье: этнические особенности дислипидемии / Г. М. Орлова, А. Л. Небесных // Атеросклероз и дислипидемии. – 2015. – № 2. – C. 30–34.
3. Tracy R. P. Inflammation, the metabolic syndrome and cardiovascular risk // Int. J. Clin. Pract. Suppl. 2003 Mar. (134). P. 10–17.
4. Ndumele C. E., Pradhan A. D., Ridker P. M. Interrelationships between inflammation, C-reactive protein, and insulin resistance // J. Cardiometab. Syndr. 2006. Summer. Vol. 1 (3). P. 190–196.
5. Szmitko P. E., Verma S., Assman G., Cullen P., Shulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study // Circulation. 2002. Vol. 105. P. 310–315.
6. Cai D., Liu T. Inflammatory cause of metabolic syndrome via brain stress and NF-κB // Aging (Albany NY). 2012. Vol. 4 (2). P. 98–115.
7. Wellen K. E., Hotamisligil G. S. Obesity-induced inflammatory changes in adipose tissue // J. Clin. Invest. 2003. Vol. 112. P. 1785–1788.
8. Шварц В. Я. Воспаление жировой ткани. Часть 3. Патогенетическая роль в развитии атеросклероза // Пробл. эндокринологии. – 2009. – Т. 55, № 6. – С. 40–45.
9. Шварц В. Я. Воспаление жировой ткани и атеросклероз / В. Я. Шварц // Кардиология. – 2009. – Т. 49, № 12. – С. 80–86.
10. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a metaanalysis // Amer. J. Med. 2006. Vol. 119. P. 812–819.
11. Шварц В. Я. Воспаление жировой ткани. Часть 1. Морфологические и функциональные проявления // Пробл. эндокринологии. – 2009. – T. 55, № 4. – C. 44–49.
12. Walldius G., Aastveit A. H., Jungner I. Stroke mortality and the apo B/apo A-I ratio: results of the AMORIS prospective study // J. Intern. Med. 2006. Vol. 259, N 3. P. 259–266.
13. Сафарова М. С. Липопротеид(а) как фактор риска сердечно-сосудистых заболеваний: современное состояние вопроса / М. С. Сафарова, М. В. Ежов // Атеросклероз и дислипидемии. – 2011. – № 1 (2). – С. 6–17.
14. Boucher J., Masri B., Daviaud D. et al. Apelin, a newly identified adipokine upregulated by insulin and obesity // Endocrinology 2005. Vol. 146, N 4. P. 1764–1771.
15. Castan-Laurell I., Vitkova M., Daviaud D. et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ // Eur. J. Endocrinol. 2008. Vol. 158, N 6. P. 905–910.
16. Rowyda Nawwaf Al-Harithy. Serum Apelin-12 Concentration in Saudi Obese Middle-Aged Men // Life Sci. J. 2014. Vol. 11 (10). P. 1113–1117.
17. Tapan S., Tascilar E., Abaci A. et al. Decreased plasma apelin levels in pubertal obese children // J. Pediatr. Endocrinol. Metab. 2010. Vol. 23, N 10. P. 1039–1046.
18. Hala O. EI-Mesallamy, Salwa M. Suwailem, Mae M. Seleem. Visfatin and apelin are new interrelated adi-pokines playing role in the pathogenesis of type 2 diabetes mellitus associated coronary artery disease in postmenopausal women // Int. Scholarly and Sci. Research & Innovation. 2013. Vol. 7, N 12. P. 447–452.
19. Sarah L. Pitkin, Janet J. Maguire, Rhoda E. Kuc, Anthony P. Davenport. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man // British J. Pharmacol. 2010. Vol. 160. P. 1785–1795.
20. Аронов Д. М. Некоторые аспекты патогенеза атеросклероза / Д. М. Аронов, В. П. Лупанов // Атеросклероз и дислипидемии. – 2011. – № 1. – C. 48–56.
21. Abu-Amero K. K., Al-Boudari O. M., Mohamed G. H., Dzimiri N. E-selectin S128R polymorphism and severe coronary artery disease in Arabs // BMC Med. Genet. 2006. Jun. Vol. 6. P. 7–52.
Review
For citations:
Efremushkina A.A., Rudakova D.M., Vorobyova E.N. Features and clinical significance of inflammatory markers in patients with metabolic syndrome with and without coronary heart disease. Ateroscleroz. 2015;11(3):51-55. (In Russ.)
Views:
156
Email this article 